- Home
- ERII vs AKBA Comparison
ERII vs AKBA Comparison
Compare ERII & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERII
- AKBA
- Stock Information
- Founded
- ERII 1992
- AKBA 2007
- Country
- ERII United States
- AKBA United States
- Employees
- ERII N/A
- AKBA N/A
- Industry
- ERII Industrial Machinery/Components
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- ERII Technology
- AKBA Health Care
- Exchange
- ERII Nasdaq
- AKBA Nasdaq
- Market Cap
- ERII 740.3M
- AKBA 729.1M
- IPO Year
- ERII 2008
- AKBA 2014
- Fundamental
- Price
- ERII $14.36
- AKBA $1.75
- Analyst Decision
- ERII Buy
- AKBA Strong Buy
- Analyst Count
- ERII 4
- AKBA 6
- Target Price
- ERII $18.75
- AKBA $6.25
- AVG Volume (30 Days)
- ERII 576.5K
- AKBA 5.7M
- Earning Date
- ERII 11-05-2025
- AKBA 11-10-2025
- Dividend Yield
- ERII N/A
- AKBA N/A
- EPS Growth
- ERII 7.56
- AKBA N/A
- EPS
- ERII 0.36
- AKBA N/A
- Revenue
- ERII $135,191,000.00
- AKBA $225,071,000.00
- Revenue This Year
- ERII $6.16
- AKBA $53.38
- Revenue Next Year
- ERII $13.06
- AKBA $30.53
- P/E Ratio
- ERII $40.74
- AKBA N/A
- Revenue Growth
- ERII 0.10
- AKBA 32.49
- 52 Week Low
- ERII $10.86
- AKBA $1.52
- 52 Week High
- ERII $19.82
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- ERII 36.38
- AKBA 29.97
- Support Level
- ERII $13.89
- AKBA $1.57
- Resistance Level
- ERII $14.65
- AKBA $1.89
- Average True Range (ATR)
- ERII 0.56
- AKBA 0.15
- MACD
- ERII -0.34
- AKBA -0.05
- Stochastic Oscillator
- ERII 20.38
- AKBA 10.33
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.